Mortality and morbidity of newly diagnosed heart failure treated with statins. A propensity-adjusted cohort study

International Journal of Cardiology

Volumn 140, Issue 2, 2010, Pages 210-218

  Gomez Soto, Francisco M ^a   Romero, Sotero P ^a   Bernal, Jose A ^a   Escobar, Miguel A ^a   Puerto, Jose L ^a   Andrey, Jose L ^a   Ruiz, Pedro ^a   Gomez, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

Heart failure; Heart failure, non systolic; Heart failure, systolic; Hydroxymethyl glutaril coenzyme A reductase inhibitors; Mortality; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, DIASTOLIC; HEART FAILURE, SYSTOLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MORBIDITY; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 77950369988     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.042     Document Type: Article

References (37)

1. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
2. Mozaffarian D., Nye R., and Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
3. Ray J.G., Gong Y., Sykora K., and Tu J.V. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 (2005) 62-67
4. Wright R.S., Bybee K.A., Miller W.L., Laudon D.A., Murphy J.G., and Jaffe A.S. Reduced risks of death are associated with statin therapy administered acutely within the first 24 h of AMI. Int J Cardiol 108 (2006) 314-319
5. Loh P.H., Windram J.D., Tin L., et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am Heart J 153 (2007) 537-544
6. Fukuta H., Sane D.C., Brucks S., and Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation 112 (2005) 37-363
7. Folkeringa R.J., Van Kraaij D.J., Tieleman R.G., Wieman F.H., Pinto Y.M., and Crijns H.J. Statins associated with reduced mortality in patients admitted for congestive heart failure. J cardia Fail 12 (2006) 134-138
8. Foody J.M., Shah R., Galusha D., Masoudi F.A., Havranek E.P., and Krumholz H.M. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
9. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
10. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G.F., and CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
11. Masoudi F.A. Statins for ischemic systolic heart failure. N Engl J Med 357 (2007) 2301-2304
12. Tavazzi L., Tognoni G., Franzosi M.G., et al. Rational and design of the GISSI heart failure trial: a large trial to assess the effects of N-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
13. McKee P.A., Castelli W.P., McNamara P.M., and Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
14. Grupo para la Atención Médica Integrada y Contínua de Cádiz (GAMIC). La consultoría de Medicina Interna en Atención Primaria mejora la eficacia de la atención médica. Med Clin (Barc) 122 (2004) 46-52
15. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
16. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
17. Rule A.D., Larson T.S., Bergstralh E.J., Slezak J.M., Jacobsen S.J., and Cosio F.G. Using serum creatinine glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141 (2004) 929-937
18. Mottram P.M., and Marwick T.H. Assessment of diastolic function: what the general cardiologist needs to know. Heart 91 (2005) 681-695
19. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.B., and Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
20. Thomas M.D., Fox K.E., Cotas A.J.S., and Sutton G.C. The epidemiological enigma of heart failure with preserved systolic function. Eur J Heart Fail 6 (2004) 125-136
21. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
22. Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
23. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
24. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335 (1996) 1001-1009
25. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
26. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
27. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
28. Cannon C.P., Braunwald E., McCabe C.H., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
29. Pedersen T.R., Faegerman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
30. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
31. Amarenco P., Bogousslavsky J., Callaham III A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
32. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
33. Lee D., Austin P., Rouleau J., Liu P., Naimark D., and Tu J. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
34. Therneau T.M., and Grambsch P.M. Modeling survival data: extending the Cox model (2000), Springer, New York, NY
35. Steg P.G., Joubin L., McCord J., et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128 (2005) 21-29
36. Doust J.A., Pietrzak E., Dobson A., and Glasziou P.P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 330 (2005) 1-9
37. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150